![David Weiner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Weiner
Technik-/Wissenschafts-/F&E-Leiter bei
CHEMOMAB THERAPEUTICS LTD.
Profil
David M.
Weiner is currently Co-Chairman at 28bio, Inc. since 2024, Director at Novoron Bioscience, Inc., Independent Non-Executive Director at Bright Minds Biosciences, Inc. since 2023, Independent Director at Eleusis Ltd., Chief Medical Officer at SwanBio Therapeutics, Inc., and will be Chief Medical Officer at Chemomab Therapeutics Ltd. starting in 2025.
Former roles include Chief Executive Officer at Amathus Therapeutics, Inc., Senior Medical Director at ACADIA Pharmaceuticals, Inc., Chief Medical Officer at aTyr Pharma, Inc. from 2014 to 2015, Faculty Member at the University of California San Diego, Faculty Member at the University of Vermont, Vice President & Head-Early Clinical Development at EMD Serono, Inc., Chief Executive & Medical Officer at Proteostasis Therapeutics, Inc., Chief Medical Officer at Lumos Pharma Sub, Inc., and Chief Medical Officer at Chemomab Therapeutics Ltd. from 2021 to 2022.
Education includes undergraduate studies at Brandeis University and a doctorate from UB School of Medicine & Biomedical Sciences.
Aktive Positionen von David Weiner
| Unternehmen | Position | Beginn |
|---|---|---|
| BRIGHT MINDS BIOSCIENCES INC. | Direktor/Vorstandsmitglied | 17.02.2023 |
| CHEMOMAB THERAPEUTICS LTD. | Technik-/Wissenschafts-/F&E-Leiter | 15.04.2025 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Technik-/Wissenschafts-/F&E-Leiter | - |
AxoSim, Inc.
 AxoSim, Inc. Packaged SoftwareTechnology Services Develops engineered human brain and peripheral nerve organoid models by integrating tissue engineering, neural interfacing and AI | Vorsitzender | 28.02.2024 |
Novoron Bioscience, Inc.
 Novoron Bioscience, Inc. BiotechnologyHealth Technology Develops novel therapeutic for disorders of the central nervous system | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von David Weiner
| Unternehmen | Position | Ende |
|---|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Technik-/Wissenschafts-/F&E-Leiter | 14.11.2022 |
| ATYR PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.07.2015 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| ░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von David Weiner
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
50
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
aTyr Pharma, Inc.
 aTyr Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a bio therapeutics company that discovers and develops medicines based on novel biological pathways | Health Technology |
Brandeis University
 Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Vermont
 University of Vermont Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Develops disease-modifying therapeutics for orphan and neurodegenerative diseases | Health Technology |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Health Services |
UB School of Medicine & Biomedical Sciences
 UB School of Medicine & Biomedical Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AxoSim, Inc.
AxoSim, Inc. Packaged SoftwareTechnology Services Develops engineered human brain and peripheral nerve organoid models by integrating tissue engineering, neural interfacing and AI | Technology Services |
Novoron Bioscience, Inc.
Novoron Bioscience, Inc. BiotechnologyHealth Technology Develops novel therapeutic for disorders of the central nervous system | Health Technology |
Amathus Therapeutics, Inc.
 Amathus Therapeutics, Inc. Investment ManagersFinance Functions as a venture capital firm that investments in biotechnology and healthcare industry | Finance |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Health Technology |
Bright Minds Biosciences, Inc.
 Bright Minds Biosciences, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Chemomab Therapeutics Ltd.
 Chemomab Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotech company | Health Technology |
